Head-To-Head Review: Enlivex Therapeutics (NASDAQ:ENLV) vs. Recursion Pharmaceuticals (NASDAQ:RXRX)

Recursion Pharmaceuticals (NASDAQ:RXRX) and Enlivex Therapeutics (NASDAQ:ENLV) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Profitability

This table compares Recursion Pharmaceuticals and Enlivex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-1,637.81%	-72.74%	-52.46%
Enlivex Therapeutics	N/A	-62.91%	-53.33%

Institutional & Insider Ownership

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

Recursion Pharmaceuticals has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.

Earnings and Valuation

This table compares Recursion Pharmaceuticals and Enlivex Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$58.84 million	38.17	-$463.66 million	($1.80)	-2.40
Enlivex Therapeutics	N/A	N/A	-$15.01 million	($0.55)	-1.89

Enlivex Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Recursion Pharmaceuticals and Enlivex Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1	3	2	0	2.17
Enlivex Therapeutics	1	2	1	0	2.00

Recursion Pharmaceuticals currently has a consensus price target of $9.40, suggesting a potential upside of 117.59%. Enlivex Therapeutics has a consensus price target of $13.00, suggesting a potential upside of 1,150.00%. Given Enlivex Therapeutics’ higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than Recursion Pharmaceuticals.

Summary

Enlivex Therapeutics beats Recursion Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.